Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBP-102
- Development stage
- Preclinical
- Lead developer
- SML Biopharm
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous, Intramuscular
01
Overview
SBP-102 is an mRNA-based cancer vaccine and bispecific antibody (bsAb) therapeutic candidate being developed by SML Biopharm. Built on the company's proprietary mRNA/LNP (lipid nanoparticle) platform, SBP-102 is designed to treat Head and Neck Squamous Cell Carcinoma (HNSCC) by leveraging mRNA to express a bispecific antibody in vivo, thereby stimulating a targeted immune response against tumor cells. The program is currently in the candidate optimization stage and is categorized within SML Biopharm's 'Immune Response Based Therapeutics' portfolio.
Beyond the preview
Go deeper on SBP-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBP-102.